Recombinant Human EPHB6 protein (rFc Tag)
Species
Human
Purity
>90 %, SDS-PAGE
Tag
rFc Tag
Activity
not tested
Cat no : Eg4219
Validation Data Gallery
Product Information
| Purity | >90 %, SDS-PAGE |
| Endotoxin | <0.1 EU/μg protein, LAL method |
| Activity |
Not tested |
| Expression | HEK293-derived Human EPHB6 protein Leu32-Ser594 (Accession# O15197-1) with a rabbit IgG Fc tag at the C-terminus. |
| GeneID | 2051 |
| Accession | O15197-1 |
| PredictedSize | 86.4 kDa |
| SDS-PAGE | 85-100 kDa, reducing (R) conditions |
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
| Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
| Storage Conditions |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
EPHB6 (Eph receptor B6) belongs to the Eph receptor family and is a receptor tyrosine pseudokinase that lacks intrinsic kinase activity and regulates cell adhesion and migration by binding to ephrin-B family proteins. EphB6 is a protein expressed in all tissues, and has been shown to be important for the maintenance of physiological homeostasis in areas such as the kidneys, vascular smooth muscle, and immune system T cells. EphB6 is a protein expressed in all tissues and has been shown to be important for the maintenance of physiological homeostasis in areas such as the kidney, vascular smooth muscle and T cells of the immune system. (PMID: 34360976) The role of EphB6 in cancer is quite complex as it not only down-regulates and inhibits the invasiveness of a wide range of malignant tumors and cancer cells, but also supports tumorigenesis in colorectal and breast cancers. It is now suggested that the interaction of EphB6 and hepcidin B1 may control tumorigenesis, e.g., the co-aggregation of EphB6 and ephrinB1 reduced the invasiveness of the breast cancer cell line MDA-MB-231.
References:
1. Strozen TG, et al. Int J Mol Sci. 2021;22(15):8211. 2. Liang LY, et al. Commun Biol. 2024;7(1):461.
